

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by China Pioneer Pharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This announcement is made to update the shareholders and potential investors of the Company on the Group’s cooperation with Alcon Pharmaceuticals Ltd. (“**Alcon**”). The Group has been the sole provider of channel management services for all of Alcon’s ophthalmic pharmaceutical products in China, and has also been providing Alcon with co-promotion services. For the year ended 31 December 2016, the Group’s revenue generated from Alcon’s ophthalmic pharmaceutical products amounted to RMB1,018.5 million, representing approximately 56.9% of the Group’s total revenue, and the Group’s gross profit generated from Alcon’s ophthalmic pharmaceutical products amounted to RMB108.5 million, representing approximately 18.3% of the Group’s total gross profit. The current cooperation agreement entered into between the Group and Alcon is due to expire on 31 December 2018. Alcon has indicated to the Group that it does not intend to extend the agreement on the same terms following its expiry. The Group is now in talks with Alcon regarding other possible future cooperation arrangements, but as at the date of this announcement, it has not entered into any formal agreement with Alcon on any arrangements after the expiry of the current cooperation agreement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Pioneer Pharma Holdings Limited
Li Xinzhou
Chairman

Hong Kong, 23 August 2017

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou and Mr. ZHU Mengjun as executive directors, Mr. WANG Yinying and Mr. WU Mijia as non-executive directors and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive directors.